Which medications in the drug class Antiglaucoma Fixed Combination Formulations, Ophthalmic are used in the treatment of Juvenile Glaucoma?

Updated: Jun 25, 2020
  • Author: Andrew A Dahl, MD, FACS; Chief Editor: Hampton Roy, Sr, MD  more...
  • Print

Antiglaucoma Fixed Combination Formulations, Ophthalmic

Combination solution may further decrease aqueous humor secretion compared to each solution used as monotherapy, while improving compliance. These agents have been approved by the FDA for children aged 2 years or older.

Brinzolamide/brimonidine (Simbrinza)

This combination product contains the carbonic anhydrase inhibitor brinzolamide and the alpha2 adrenergic receptor agonist brimonidine. It is indicated for reduction of elevated intraocular pressure in patients with primary open-angle glaucoma.

Timolol/brimonidine (Combigan)

Brimonidine is a selective alpha2 adrenergic receptor agonist and timolol is a nonselective beta-adrenergic receptor inhibitor. Each of these agents decrease elevated IOP, whether or not associated with glaucoma.

Timolol/dorzolamide (Cosopt)

Dorzolamide is a carbonic anhydrase inhibitor that decreases aqueous humor secretion, causing a decrease in IOP. This agent presumably slows bicarbonate ion formation with subsequent reduction in sodium and fluid transport. Timolol is a nonselective beta-adrenergic receptor blocker that decreases IOP by decreasing aqueous humor secretion.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!